Genomics England’s Generation Study
We are thrilled to announce the launch of the Generation Study, which will test newborns for changes in genes linked to over 200 rare genetic conditions. The research is run by Genomics England who partner with the NHS to provide whole genome sequencing diagnostics....
New research released
Beyond the patient - understanding the spillover effects of XLH. XLH UK is pleased to have collaborated with researchers on an original study which is the first to identify the impacts of XLH beyond the patient alone. The study was initiated and funded by Kyowa Kirin...
NICE decision gives UK-wide access to burosumab
XLH UK is delighted to report that adults living with XLH in England, Wales and Northern Ireland will now have access to burosumab, the first available treatment to tackle the underlying cause of XLH. The decision by NICE ensures equal access to burosumab across the...
XLH UK Community event is announced
We are pleased to announce that the next XLH UK Community Day will take place on Sunday 2nd June 2024. Our annual event will be bigger and better than ever. For how the day went, follow the link here. It will be held at the National Conference Centre, Birmingham. The...
XLH UK Interviews gymnast Kieron Innes
We kicked off 2024 chatting with 17-year-old Kieron Innes, a talented gymnast living with XLH. Kieron was diagnosed with XLH when he was already years into his impressive gymnastics journey. In the interview, we hear about some of the tough mental and physical...
Making the XLH Patient Stories
In 2023, XLH UK collaborated with Joe Bonnell, a photographic ethnographer, and filmmaker Rachel Lewis to capture the stories of some of the XLH community. I sat down with Sarah Mitson, Chair of XLH UK, to explore the motivation behind commissioning these powerful...
Scotland confirms burosumab for children
XLH UK is pleased to to report that the Scottish Medicines Consortium (SMC) has confirmed access to burosumab (marketed as Crysvita) for the treatment of X-linked hypophosphataemia (XLH) in children and adolescents aged 1 to 17 years with radiographic evidence of bone...
XLH UK campaign on BBC News
As part of our Call to Action, members of the XLH community have been talking to the press about the draft guidance from NICE to reject burosumab for adult patients. We are thrilled to see that our message has been highlighted by both BBC Wales and BBC NorthWest! You...
NICE guidance rejects burosumab for adults
NICE has released draft guidance on the Health Technology Assessment of burosumab for adults in England. Their evaluation and XLH UK's response is explained in the press release below, along with a five step Call to Action! for all members of the XLH community. ...
XLH UK Newsletter – October 2023
Welcome to XLH’s Navigator newsletter for Autumn 2023. Hear about our recent Connect meeting and a visit to the Welsh Parliament. Don’t miss the next newsletter and subscribe here: https://xlhuk.org/registration-form/ You can view it here:...
XLH UK visit the Welsh Parliament
At a recent Senedd roundtable event, Oliver Gardiner, representing XLH UK, and Claire Lewis, a Welsh XLH patient, were joined by Mike Hedges MS. Mike Hedges, who chairs the Senedd Cross Party Group on Rare Diseases, brought invaluable expertise and leadership to the...
XLH UK Competition Winner
Thank you to everyone who suggested some brilliant names for our new XLH UK mascot! It was very hard to pick just one, but we’re pleased to say that the winning name is HUXLEY. Jane, her granddaughters and the cute soft toy family made by...
Oliver represents XLH UK at The Houses of Parliament
"An afternoon of enlightening talks and updates!" The Brittle Bone Society (BBS) recently organised an event held at the Houses of Parliament in London to bring the OI CAN campaign to the attention of policymakers. Developments supporting those with Osteogenesis...
XLH UK Newsletter – July 2023
Welcome to XLH's Navigator newsletter for Summer 2023. Hear about our the Family Day and Oliver's visit to the Houses of Parliament. Don't miss the next newsletter and subscribe here: https://xlhuk.org/registration-form/ You can view it here:...
XLH UK recognised in PPI 2023 Awards
Newsflash! We are delighted to announce that the partnership between Kyowa Kirin and XLH UK has been recognised in the PPI 2023 Awards. This is for a partnership that led to a framework of a networked service model on care of adults with rare bone conditions. For more...
XLH UK Competition Time!
Thank you to Anne Williams who attended our recent family day in Bristol and brought this cute soft toy family with her. Anne has kindly donated them, and we need some help to name them because the little one is going to become our XLH UK mascot, welcoming newly...
XLH UK Family Day, Sunday 21st May 2023 “…Another great meet-up! Roll on the next!”
The 52 people who attended our Family Day on 21st May were kind enough to bring the sunshine with them, thank you! From as far afield as Manchester, London and even Belfast, XLHers and their families came to Engineers’ House, Clifton, Bristol, to share their...
XLH UK Newsletter – Navigator Spring 2023 Edition
Welcome to XLH's Navigator newsletter for Spring 2023. Hear about our upcoming Family Day and how a team in Northern Ireland have been inspiring us with their fitness and fundraising! Don't miss the next newsletter and subscribe here:...
XLH UK Newsletter – Navigator 3rd Edition
Welcome to XLH's 3rd edition Navigator newsletter. Hear about how new medicines get approved for funding and the priorities XLH UK has set to help all those with XLH find their best care. Don't miss the next newsletter and subscribe here:...
Scotland grants XLH adults access to burosumab
XLH UK founder Oliver Gardiner: “This is fantastic news for adults with XLH in Scotland and is a leap forward, setting a precedent as the first of the UK nations to recommend burosumab for the eligible adult population. This life-changing treatment is the first to...